As Rowse expands from skincare to make-up, Wallpaper* speaks exclusively with co-founders Nuria Val and Gabriela Salord about ...

Rather, with so much uncertainty, investors are prizing biotech companies that base their intellectual property and manufacturing in the U.S., which up until now often meant higher taxes.

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry. For many companies, Kendall Square’s status as a global center of biotechnology firms and ...

As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and stopping clinical development of its lead program to hunker down and ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should ...

Biotechnology offers a scalable alternative, but realizing its full potential requires commitment from governments and space agencies. By harnessing biological processes such as microbial and ...

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. The industry has recovered from a challenging 2024 and is ...

Some hoped the biotech's stock could soar due to another company acquiring it, but that now seems unlikely. The drugmaker is a fairly attractive long-term option regardless of Wall Street's price ...